[go: up one dir, main page]

Steuten et al., 2021 - Google Patents

Challenges for targeting SARS-CoV-2 proteases as a therapeutic strategy for COVID-19

Steuten et al., 2021

View PDF
Document ID
3242695233519085497
Author
Steuten K
Kim H
Widen J
Babin B
Onguka O
Lovell S
Bolgi O
Cerikan B
Neufeldt C
Cortese M
Muir R
Bennett J
Geiss-Friedlander R
Peters C
Bartenschlager R
Bogyo M
Publication year
Publication venue
ACS infectious diseases

External Links

Snippet

Two proteases produced by the SARS-CoV-2 virus, the main protease and papain-like protease, are essential for viral replication and have become the focus of drug development programs for treatment of COVID-19. We screened a highly focused library of compounds …
Continue reading at pmc.ncbi.nlm.nih.gov (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

Similar Documents

Publication Publication Date Title
Steuten et al. Challenges for targeting SARS-CoV-2 proteases as a therapeutic strategy for COVID-19
Mellott et al. A clinical-stage cysteine protease inhibitor blocks SARS-CoV-2 infection of human and monkey cells
Cannalire et al. SARS-CoV-2 entry inhibitors: small molecules and peptides targeting virus or host cells
Ma et al. Ebselen, disulfiram, carmofur, PX-12, tideglusib, and shikonin are nonspecific promiscuous SARS-CoV-2 main protease inhibitors
Mengist et al. Structural basis of potential inhibitors targeting SARS-CoV-2 main protease
Ashhurst et al. Potent anti-SARS-CoV-2 activity by the natural product gallinamide A and analogues via inhibition of cathepsin L
Tan et al. Progress and challenges in targeting the SARS-CoV-2 papain-like protease
Verma et al. Proton-coupled conformational activation of SARS coronavirus main proteases and opportunity for designing small-molecule broad-spectrum targeted covalent inhibitors
Xu et al. Broad spectrum antiviral agent niclosamide and its therapeutic potential
Nitsche et al. De novo discovery of nonstandard macrocyclic peptides as noncompetitive inhibitors of the Zika virus NS2B-NS3 protease
Calleja et al. Inhibitors of sars-cov-2 plpro
Johansen-Leete et al. Antiviral cyclic peptides targeting the main protease of SARS-CoV-2
Gao et al. Perspectives on SARS-CoV-2 main protease inhibitors
Nitsche et al. Biochemistry and medicinal chemistry of the dengue virus protease
Behnam et al. Discovery of nanomolar dengue and west nile virus protease inhibitors containing a 4-benzyloxyphenylglycine residue
Weigel et al. Phenylalanine and phenylglycine analogues as arginine mimetics in dengue protease inhibitors
Hariono et al. Thioguanine-based DENV-2 NS2B/NS3 protease inhibitors: Virtual screening, synthesis, biological evaluation and molecular modelling
Rothan et al. Protegrin‐1 Inhibits Dengue NS2B‐NS3 Serine Protease and Viral Replication in MK2 Cells
Stoermer et al. Potent cationic inhibitors of West Nile virus NS2B/NS3 protease with serum stability, cell permeability and antiviral activity
Behnam et al. C-terminal residue optimization and fragment merging: discovery of a potent peptide-hybrid inhibitor of dengue protease
Yuan et al. Targeting papain-like protease for broad-spectrum coronavirus inhibition
Osman et al. Why all the fury over furin?
Cao et al. Evaluation of SARS-CoV-2 main protease inhibitors using a novel cell-based assay
Lim et al. Curcumin allosterically inhibits the dengue NS2B-NS3 protease by disrupting its active conformation
Zu et al. Peptide inhibitor of Japanese encephalitis virus infection targeting envelope protein domain III